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S 4 ( 2 0 0 6 ) 2 7 –5 3Background: Previously we showed that oncogene Ha-Ras stim-ulates the metastatic activity of both spontaneously transformed
and v-src-transformed Syrian hamster fibroblasts in vivo. We
revealed that Ha-Ras/RalGDS/Ral-associated signalling pathway
was the most important for metastasis among the variety of
Ha-Ras associated signaling cascades.
Methods: Retroviral infection, molecular cloning, spontaneous
metastatic activity, gelatine zymography, RT-PCR, cell viability
assay, peroxide decomposition activity assay.
Results: We showed that both RalA and RalB stimulate the meta-
static potential of cells, but RalB is less efficient than RalA. To
understand what Ral interacting proteins contribute to this phe-
nomenon we compared the level of metastatic potential of the cell
lines expressing RalA and RalB effecter domain mutants. The
search revealed that among the three best-studied Ral downstream
partners RalA-PLD1 and RalB-RalBP1/RalB-Sec5 interactions were
essential. The introduction of active form of RalA (RalA+ cells),
unlike RalB, downregulates the secretion of MMP1, MMP2 and
MMP9 in comparison to parental cells, although the cocultivation
of RalA+ cells with hamster embryo fibroblasts leaded to stimula-
tion of MMPs secretion suggesting that RalA+ cells can it in stromal
cells. The highly metastatic cells acquired the peroxide resistance
as well as peroxide decomposition activity and this viability may
serve as a protection against the host immune system.
Conclusion: RalB can stimulate metastatic ability of transformed
cells, but less than RalA. These two closely-related proteins prob-
ably stimulate metastasis through distinct downstream signaling
pathways. MMPs secretion is involved in Ral-dependent metasta-
sis, but RalA and RalB utilize different cellular mechanisms.
doi:10.1016/j.ejcsup.2006.04.073
P14. ADAM-17: A MEDIATOR OF BREAST CANCER
PROGRESSION?
Patricia McGowana, Brid Ryana, Arnold Hillb, Enda McDermottb,
Niall O’Higginsb, Michael J. Duffya,b. aUCD School of Biomolecular
and Biomedical Science, Conway Institute, University College Dublin,
Dublin 4, Ireland; bEducation and Research Centre, St. Vincent’s
University Hospital, Dublin 4, Ireland.
Background: The ADAMs are a family of transmembrane, multi-
domain proteins, involved in both cellular adhesion and proteol-
ysis. Multiple studies from model systems suggest that specific
ADAMs are involved in cancer progression. The aim of this inves-
tigation was to see if ADAM-17 was involved in the progression of
human breast cancer.
Materials, Methods and Results: ADAM-17 protein was mea-
sured by both Western blotting and ELISA. ADAM-17 protein
was found to exist in two main forms in human breast tissue, a
120 kDa precursor and 100 kDa active protein. Both forms of
ADAM-17 protein were found to be upregulated in primary breast
carcinomas compared to normal breast tissue (Mann–Whitney U-
test: p = 0.005, p = 0.0003, respectively). The ratio of 100 kDa pro-
tein to 120 kDa protein increased with disease progression from
normal breast tissue to axillary node metastases (Kruskal–Wallis
statistical test: p = 0.002), indicating an increase in processing
from precursor to active protein in malignant breast tissue.
32 E J C S U P P L E M E N TA moderate, but significant correlation was found between the
100 kDa form of ADAM-17 (measured by Western blotting) and
ADAM-17 levels determined by ELISA (Spearman Rank:
p = 0.0006, r = 0.405). No significant relationship was found
between the 120 kDa protein form and levels measured by ELISA.
ADAM-17 protein levels, as measured by ELISA, were significantly
higher in grade 3 tumours as compared to tumours classed as
grades 1 and 2 (Mann–Whitney U-test: p = 0.03), and in node-posi-
tive compared to node-negative cancers (Mann–Whitney U-test:
p = 0.04). Furthermore, both forms of ADAM-17 correlated with
cell proliferation, as measured by PCNA (Spearman Rank:
r = 0.524, p < 0.0001; r = 0.365, p = 0.002, respectively) and with
metastatic potential, as measured by uPA (Spearman Rank:
r = 0.246, p = 0.032; r = 0.428, p = 0.0001, respectively).
Conclusion: We conclude that ADAM-17 protein exists in two
main forms in breast cancer. Furthermore, our results suggest
that ADAM-17 is involved in breast cancer progression.
doi:10.1016/j.ejcsup.2006.04.074
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Background: Pancreatic cancer is the fifth most frequent cause of
cancer-related deaths in industrialized countries. The diagnosis of
ductal adenocarcinoma of the pancreas is associated with a poor
prognosis, an increasing incidence and no or only ineffective
means of treatment. Cystic pancreatic neoplasms account only
approximately 5% of primary malignancies of the pancreas and
may be benign, pre-malignant or malignant. In this study, we are
developing and evaluating a DNA-diagnostic-chip with about 3500
human genes known to be differentially transcribed in pancreatic
cancer cells and thus expected to show a representative expression
pattern in both ductal adenocarcinoma and cystic lesions.
Methods: cDNAs representing different human genes were PCR-
amplified, purified and robotically arrayed onto slides with an
epoxy surface. Fluorescently labelled cDNA samples were pre-
pared from total RNA isolated from cells of human pancreas tissue
by incorporation of labelled dCTPs during reverse transcription.
Results: Microarray experiments on various samples are being
performed and analysed allowing classification of different types
of pancreas lesions and the identification of potential targets as a
means of eventually developing new modes of treatment.
Conclusion: The resulting diagnostic DNA-chip will be of signif-
icant clinical utility to detect cancer cells in tissues from patients
with different types of pancreatic carcinoma and to draw prog-
nostic conclusions based on their molecular appearance. Further-
more, comparative studies on transcriptional profiling and actual
protein expression by means of complex DNA- and antibody
microarrays are under way.
doi:10.1016/j.ejcsup.2006.04.075
